|
US20090191213A9
(en)
*
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
ES2732623T3
(es)
*
|
2005-01-06 |
2019-11-25 |
Innate Pharma Sa |
Tratamientos y métodos de combinación anti-KIR
|
|
JP6342325B2
(ja)
*
|
2011-05-25 |
2018-06-13 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
炎症性障害の治療のための抗ｋｉｒ抗体
|
|
WO2014037422A1
(en)
*
|
2012-09-04 |
2014-03-13 |
Inven2 As |
Selective and controlled expansion of educated nk cells
|
|
EP2904011B1
(en)
|
2012-10-02 |
2017-08-23 |
Bristol-Myers Squibb Company |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
|
CN105188749B
(zh)
|
2012-12-21 |
2017-12-19 |
西雅图基因公司 |
抗ntb‑a抗体及相关组合物和方法
|
|
WO2014117121A1
(en)
|
2013-01-28 |
2014-07-31 |
St. Jude Children's Research Hospital, Inc. |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
WO2014179759A1
(en)
|
2013-05-03 |
2014-11-06 |
Ohio State Innovation Foundation |
Cs1-specific chimeric antigen receptor engineered immune effector cells
|
|
US10494433B2
(en)
|
2013-11-06 |
2019-12-03 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
|
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
WO2015195555A1
(en)
*
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
|
US10617757B2
(en)
|
2014-08-08 |
2020-04-14 |
The Regents Of The University Of California |
Methods for treating multiple myeloma
|
|
KR102606190B1
(ko)
|
2015-02-20 |
2023-11-23 |
오하이오 스테이트 이노베이션 파운데이션 |
Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
|
|
RU2571551C1
(ru)
*
|
2015-04-16 |
2015-12-20 |
Закрытое акционерное общество "ПЕПТЕК" |
Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
|
|
DK3283107T3
(da)
|
2015-04-17 |
2020-08-31 |
Bristol Myers Squibb Co |
Sammensætninger omfattende en kombination af ipilimumab og nivolumab
|
|
EP3907285A1
(en)
|
2015-05-06 |
2021-11-10 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
JP6944925B2
(ja)
|
2015-07-24 |
2021-10-06 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
組織浸潤ｎｋ細胞を検出する方法
|
|
US20190038713A1
(en)
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
JP7169195B2
(ja)
|
2016-05-20 |
2022-11-10 |
バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド |
癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
KR101926166B1
(ko)
*
|
2016-05-24 |
2018-12-06 |
재단법인 아산사회복지재단 |
수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
JP7542946B2
(ja)
|
2016-09-27 |
2024-09-02 |
ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム |
マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
|
|
MX386249B
(es)
|
2016-10-12 |
2025-03-18 |
Univ Texas |
Terapia tusc2 para usarse en el tratamiento de cáncer.
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
EP3579879A4
(en)
*
|
2017-02-09 |
2020-12-16 |
Memorial Sloan Kettering Cancer Center |
ANTI-BODY ANTI-KIR3DL1
|
|
KR102624509B1
(ko)
|
2017-03-27 |
2024-01-12 |
싱가포르국립대학교 |
자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
|
|
EP3600356A4
(en)
|
2017-03-27 |
2020-12-23 |
National University of Singapore |
TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
|
|
WO2018183928A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN121159691A
(zh)
|
2017-05-12 |
2025-12-19 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
EA202090817A1
(ru)
|
2017-10-13 |
2020-09-08 |
Харпун Терапьютикс, Инк. |
Триспецифические белки и способы их применения
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
CN112020510B
(zh)
|
2018-03-19 |
2024-10-11 |
茂体外尔公司 |
包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
|
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
|
GB2587521B
(en)
|
2018-03-25 |
2023-06-21 |
Snipr Biome Aps |
Treating & preventing microbial infections
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
US20210032344A1
(en)
|
2018-03-30 |
2021-02-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
WO2019195769A1
(en)
*
|
2018-04-06 |
2019-10-10 |
The Brigham And Women's Hospital, Inc. |
Methods of diagnosing and treating aggressive cutaneous t-cell lymphomas
|
|
CN108728527B
(zh)
*
|
2018-06-06 |
2020-06-09 |
青岛泱深生物医药有限公司 |
Hcst基因作为诊治子痫前期的靶标
|
|
JP2021528393A
(ja)
|
2018-06-15 |
2021-10-21 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
後細胞シグナル伝達因子の調節による免疫活性の上昇
|
|
CN112601758A
(zh)
|
2018-08-29 |
2021-04-02 |
新加坡国立大学 |
特异性刺激经基因修饰免疫细胞的存活和扩增的方法
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
US20220054524A1
(en)
|
2018-12-21 |
2022-02-24 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
KR102210455B1
(ko)
*
|
2019-02-28 |
2021-02-02 |
사회복지법인 삼성생명공익재단 |
자연살해세포 활성 검출용 미세입자 및 이를 이용한 검출 방법
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
CN111973739B
(zh)
*
|
2019-05-23 |
2024-02-13 |
正大天晴药业集团股份有限公司 |
抗pd-l1单克隆抗体治疗癌症的用途
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
|
WO2022011531A1
(zh)
*
|
2020-07-14 |
2022-01-20 |
浙江道尔生物科技有限公司 |
一种抗cld18a2的单域抗体
|
|
BR112023003553A2
(pt)
|
2020-08-31 |
2023-04-04 |
Bristol Myers Squibb Co |
Assinatura de localização celular e imunoterapia
|
|
WO2022108877A1
(en)
*
|
2020-11-18 |
2022-05-27 |
The Regents Of The University Of California |
Depleting monoclonal antibodies against natural killer cells
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
EP4566674A3
(en)
|
2020-12-28 |
2025-08-06 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
CA3209479A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
JP2024525758A
(ja)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
|
|
KR20240038769A
(ko)
*
|
2021-07-28 |
2024-03-25 |
머크 샤프 앤드 돔 엘엘씨 |
항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
CA3240558A1
(en)
|
2021-12-16 |
2023-06-22 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
US20250332252A1
(en)
|
2022-06-02 |
2025-10-30 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|